PI

DRUG4 trials

Sponsors

Hoffmann-La Roche, Gilead Sciences, Hospital Universitari Vall d'Hebron Research Institute

Conditions

Acquired Immunodeficiency SyndromeHIV InfectionsHIV-1HIV-1 Infection

Phase 3

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

CompletedNCT01252940

Gilead SciencesHIV-1 Infection

Start: 2010-11-30End: 2014-10-31Updated: 2015-12-04

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

CompletedNCT01475838

Gilead SciencesAcquired Immunodeficiency Syndrome, HIV Infections

Start: 2011-11-30End: 2014-12-31Updated: 2016-06-08

Phase 4

BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

CompletedNCT00326963

Hoffmann-La RocheHIV Infections

Start: 2006-03-31End: 2007-05-31Updated: 2016-08-16

HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen

CompletedNCT02513147

Hospital Universitari Vall d'Hebron Research InstituteHIV-1

Start: 2015-06-30End: 2016-11-30Updated: 2017-06-14

Related Papers

Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF.

2015-10-019 citations

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.

2014-06-0597 citations